Notice of Settlement with Aspect Biosystems, Inc.

Others | 2023-10-30

In connection with the inter partes review proceeding (IPR2023-00026) filed against a patent (U.S. Patent No. 87851; hereinafter referred to as the "Patent") for which we have an exclusive license from the University of Tokyo, a final and amicable settlement has been reached with the submitter, Aspect Biosystems, Inc.

As we expand our cell therapy business globally based on CellFiber® technology, we recognize the significance of our intellectual property rights, both owned and licensed. These rights are valuable assets that we will continue to leverage in order to enrich our company’s overall worth and bring greater value to our users and stakeholders through our commitment to the industry.